Edoxaban tosylate
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 414002

CAS#: 480449-71-6 (tosylate)

Description: Edoxaban tosylate is a prophylaxis of Thromboembolic Complications Associated with Atrialfibrillation, Treatment and Prevention of VTE


Chemical Structure

img
Edoxaban tosylate
CAS# 480449-71-6 (tosylate)

Theoretical Analysis

MedKoo Cat#: 414002
Name: Edoxaban tosylate
CAS#: 480449-71-6 (tosylate)
Chemical Formula: C31H38ClN7O7S2
Exact Mass: 719.1963
Molecular Weight: 720.26
Elemental Analysis: C, 51.70; H, 5.32; Cl, 4.92; N, 13.61; O, 15.55; S, 8.90

Price and Availability

Size Price Availability Quantity
500.0µg USD 206.0 2 Weeks
1.0mg USD 339.0 2 Weeks
5.0mg USD 645.0 2 Weeks
Bulk inquiry

Related CAS #: 1229194-11-9 (tosylate hydrate)   480449-71-6 (tosylate)   480448-29-1 (HCl)   480449-70-5 (free base)    

Synonym: Edoxaban tosylate; DU176b; DU-176b; DU 176b

IUPAC/Chemical Name: N-(5-Chloropyridin-2-yl)-N'-((1S,2R,4S)-4-(N,N-dimethylcarbamoyl)-2-(5-methyl-4,5,6,7- tetrahydro(1,3)thiazolo(5,4-c)pyridine-2-carboxamido)cyclohexyl)oxamide, 4- methylbenzenesulfonate

InChi Key: ZLFZITWZOYXXAW-QXXZOGQOSA-N

InChi Code: InChI=1S/C24H30ClN7O4S.C7H8O3S/c1-31(2)24(36)13-4-6-15(27-20(33)21(34)30-19-7-5-14(25)11-26-19)17(10-13)28-22(35)23-29-16-8-9-32(3)12-18(16)37-23;1-6-2-4-7(5-3-6)11(8,9)10/h5,7,11,13,15,17H,4,6,8-10,12H2,1-3H3,(H,27,33)(H,28,35)(H,26,30,34);2-5H,1H3,(H,8,9,10)/t13-,15-,17+;/m0./s1

SMILES Code: O=C(NC1=NC=C(Cl)C=C1)C(N[C@@H]2[C@H](NC(C(S3)=NC4=C3CN(C)CC4)=O)C[C@@H](C(N(C)C)=O)CC2)=O.O=S(C5=CC=C(C)C=C5)(O)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: To be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 720.26 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Raskob GE, van Es N, Verhamme P, Carrier M, Di Nisio M, Garcia D, Grosso MA, Kakkar AK, Kovacs MJ, Mercuri MF, Meyer G, Segers A, Shi M, Wang TF, Yeo E, Zhang G, Zwicker JI, Weitz JI, Büller HR; Hokusai VTE Cancer Investigators. Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. N Engl J Med. 2018 Feb 15;378(7):615-624. doi: 10.1056/NEJMoa1711948. Epub 2017 Dec 12. PMID: 29231094.

2: Edoxaban tosylate. Am J Cardiovasc Drugs. 2011;11(2):129-35. doi: 10.2165/11533660-000000000-00000. PMID: 21446778.

3: Okumura K, Akao M, Yoshida T, Kawata M, Okazaki O, Akashi S, Eshima K, Tanizawa K, Fukuzawa M, Hayashi T, Akishita M, Lip GYH, Yamashita T; ELDERCARE- AF Committees and Investigators. Low-Dose Edoxaban in Very Elderly Patients with Atrial Fibrillation. N Engl J Med. 2020 Oct 29;383(18):1735-1745. doi: 10.1056/NEJMoa2012883. Epub 2020 Aug 30. PMID: 32865374.

4: Vranckx P, Valgimigli M, Eckardt L, Tijssen J, Lewalter T, Gargiulo G, Batushkin V, Campo G, Lysak Z, Vakaliuk I, Milewski K, Laeis P, Reimitz PE, Smolnik R, Zierhut W, Goette A. Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial. Lancet. 2019 Oct 12;394(10206):1335-1343. doi: 10.1016/S0140-6736(19)31872-0. Epub 2019 Sep 3. PMID: 31492505.

5: Cohen AT, Hamilton M, Mitchell SA, Phatak H, Liu X, Bird A, Tushabe D, Batson S. Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis. PLoS One. 2015 Dec 30;10(12):e0144856. doi: 10.1371/journal.pone.0144856. PMID: 26716830; PMCID: PMC4696796.

6: Hussar DA, Jacob J. Edoxaban tosylate monohydrate, secukinumab, and suvorexant. J Am Pharm Assoc (2003). 2015 Sep-Oct;55(5):563-7. doi: 10.1331/JAPhA.2015.15537. PMID: 26359966.

7: Kato ET, Giugliano RP, Ruff CT, Koretsune Y, Yamashita T, Kiss RG, Nordio F, Murphy SA, Kimura T, Jin J, Lanz H, Mercuri M, Braunwald E, Antman EM. Efficacy and Safety of Edoxaban in Elderly Patients With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial. J Am Heart Assoc. 2016 May 20;5(5):e003432. doi: 10.1161/JAHA.116.003432. PMID: 27207971; PMCID: PMC4889207.

8: Lee SR, Choi EK, Han KD, Jung JH, Oh S, Lip GYH. Edoxaban in Asian Patients With Atrial Fibrillation: Effectiveness and Safety. J Am Coll Cardiol. 2018 Aug 21;72(8):838-853. doi: 10.1016/j.jacc.2018.05.066. PMID: 30115222.

9: Carnicelli AP, De Caterina R, Halperin JL, Renda G, Ruff CT, Trevisan M, Nordio F, Mercuri MF, Antman E, Giugliano RP; ENGAGE AF-TIMI 48 Investigators. Edoxaban for the Prevention of Thromboembolism in Patients With Atrial Fibrillation and Bioprosthetic Valves. Circulation. 2017 Mar 28;135(13):1273-1275. doi: 10.1161/CIRCULATIONAHA.116.026714. Epub 2017 Feb 16. PMID: 28209729.

10: Hohnloser SH, Camm J, Cappato R, Diener HC, Heidbüchel H, Mont L, Morillo CA, Abozguia K, Grimaldi M, Rauer H, Reimitz PE, Smolnik R, Mönninghoff C, Kautzner J. Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial. Eur Heart J. 2019 Sep 21;40(36):3013-3021. doi: 10.1093/eurheartj/ehz190. Erratum in: Eur Heart J. 2019 Sep 21;40(36):3043. PMID: 30976787; PMCID: PMC6754569.